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CancerThe molecular mechanisms underlying the posttranslational modiﬁcation of proteins in gastrointestinal
cancer are still unknown. Here, we investigated the role of methylglyoxal modiﬁcations in gastrointestinal
tumors. Methylglyoxal is a reactive dicarbonyl compound produced from cellular glycolytic intermediates
that reacts non-enzymatically with proteins. By using a monoclonal antibody to methylglyoxal-modiﬁed
proteins, we found that murine heat-shock protein 25 and human heat-shock protein 27 were the major
adducted proteins in rat gastric carcinoma mucosal cell line and human colon cancer cell line, respectively.
Furthermore, we found that heat-shock protein 27 was modiﬁed by methylglyoxal in ascending colon and
rectum of patients with cancer. However, methylglyoxal-modiﬁed heat-shock protein 25/heat-shock protein
27 was not detected in non cancerous cell lines or in normal subject. Matrix-associated laser desorption/
ionization mass spectrometry/mass spectrometry analysis of peptide fragments identiﬁed Arg-75, Arg-79,
Arg-89, Arg-94, Arg-127, Arg-136, Arg-140, Arg-188, and Lys-123 as methylglyoxal modiﬁcation sites in heat-
shock protein 27 and in phosphorylated heat-shock protein 27. The transfer of methylglyoxal-modiﬁed heat-
shock protein 27 into rat intestinal epithelial cell line RIE was even more effective in preventing apoptotic cell
death than that of native control heat-shock protein 27. Furthermore, methylglyoxal modiﬁcation of heat-
shock protein 27 protected the cells against both the hydrogen peroxide- and cytochrome c-mediated caspase
activation, and the hydrogen peroxide-induced production of intracellular reactive oxygen species. The levels
of lactate converted from methylglyoxal were increased in carcinoma mucosal cell lines. Our results suggest
that posttranslational modiﬁcation of heat-shock protein 27 by methylglyoxal may have important
implications for epithelial cell injury in gastrointestinal cancer.ock protein 25; Hsp27, heat-
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Most cancer cells produce energy by glycolysis rather than
oxidative phosphorylation via the tricarboxylic acid (TCA) cycle,
even in the presence of an adequate oxygen supply (Warburg effect)
[1]. Extremely low glucose, coupled with high lactate and glycolytic
intermediate concentrations, were found in tumor tissues obtained
from 16 colon and 12 stomach cancer patients, indicating enhanced
glycolysis, and thus conﬁrming the Warburg effect [2]. Methylglyoxal(MG) modiﬁes tissue proteins via the Maillard reaction, and in the
glycolytic pathway, resulting in advanced glycation end products
(AGEs) that can alter protein structure and function. In human non-
small-cell lung cancer tissues, the AGEs Nε-(carboxymethyl) lysine
(CML) and argpyrimidine have been detected by immunohistochem-
istry [3].
Small heat-shock proteins, including murine heat-shock protein
25 (Hsp25) which is the murine homolog of human heat-shock
protein 27 (Hsp27), human Hsp27, and alpha B-crystallin, are
molecular chaperones constitutively expressed in several mammalian
cells, particularly in pathological conditions [4]. Short-chain fatty
acids, such as butyrate, induce a time- and concentration-dependent
increase in Hsp25 protein expression in rat intestinal epithelial cells
[5]. Small heat-shock proteins share functions as diverse as protection
against toxicity mediated by aberrantly folded proteins, and oxida-
tive-inﬂammation conditions [4,6]. In addition, these proteins share
anti-apoptotic properties and are tumorigenic when expressed in
cancer cells [4]. Hsp27 is phosphorylated at serines 15, 78 and 82 by
mitogen-activated protein kinase associated protein kinases 2 and 3
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phosphorylation by MAP p38 protein kinase [7,8]. However, the
mechanism regulating Hsp27 action in cancer cells is still unknown. In
a previous study, we showed that Hsp27 has enhanced anti-apoptotic
properties after MG modiﬁcation in lens epithelial cells [9]. Here, we
examine the effect of MG modiﬁcation on the anti-apoptotic function
of Hsp27 in rat intestinal epithelial cell line.
2. Materials and methods
2.1. Reagents and cell culture
Human Hsp27 polyclonal and mouse Hsp25 polyclonal antibodies
were obtained from StressGen Biotechnologies Corp. (Victoria, British
Columbia, Canada). Human phosho-Hsp27 (Ser-82) polyclonal and
human Hsp27 monoclonal antibodies were obtained from Cell
Signaling Technology Japan, K.K. (Tokyo, Japan). Horseradish perox-
idase (HRP)-linked anti-rabbit IgG was obtained from Cell Signaling
Technology, Inc. (Beverly, MA, United States). HRP-linked anti-mouse
IgG, Deep Purple Total Protein Stain, Protein A Sepharose and
enhanced chemiluminescence (ECL) Plus Western blotting detection
reagents were obtained from GE Healthcare UK Ltd. (Buckingham-
shire, England). Staphylococcus aureus V8 protease (endoproteinase
Glu-C) was obtained from Wako Pure Chemical Industries, Ltd.
(Osaka, Japan). D-Lactic acid, L-lactic acid, D-lactate dehydrogenase
(D-LDH) (Lactobacillus leichmannii), L-lactate dehydrogenase (L-LDH)
(bovine heart), glutamate-pyruvate transamirase, NAD+ and pyru-
vate were purchased from J.K. International Inc. (Tokyo, Japan).
Normal rat gastric mucosal cell line RGM-1 and rat gastric carcinoma
mucosal cell line RGK-1 [10] were donated by Dr. Hirofumi Matsui of
the University of Tsukuba, Japan. RGM-1 cells, RGK-1 cells, human
colon cancer cell line HT-29, and rat intestinal epithelial cell line RIE
were grown in a 1:1 mixture of Dulbecco's modiﬁed Eagle medium
and Ham's F-12 medium (DMEM/F12; Cosmo Bio, Tokyo, Japan)
supplementedwith 10% fetal calf serum (FCS; Gibco, Grand Island, NY,
United States). Young adult mouse colon (YAMC) epithelial cells were
grown in RPMI with 5% fetal calf serum, 100 ng/μl IFN-γ, 2 mM
glutamine, 50 μg/ml gentamicin, 100 U/ml penicillin, 100 μg/ml
streptomycin, and 1× insulin/transferrin/selenium. All cells were
grown at 37 °C in a humidiﬁed 5% CO2 atmosphere.
2.2. Sample preparation
Cells were harvested by centrifugation, rinsed in phosphate-
buffered saline (PBS), and resuspended in homogenization buffer
(8 M Urea, 4% 3-[(3-cholamidopropyl)dimethylammonio]-1-propa-
nesulfonic acid (CHAPS), 40 mMTris) containing nuclease and protein
inhibitors (GE Healthcare UK Ltd.) at a volume approximately equal to
that of the packed cells. The suspension was transferred to an
ultracentrifuge tube and the nuclei were removed by centrifugation
(20 min at 20,000g, 25 °C). Lysates were precipitated using the Plus
One 2D Clean-up kit as recommended by the manufacturer (GE
Healthcare UK Ltd.). The protein concentration in the supernatant
fraction was determined using the Bradford assay, with bovine serum
albumin as the standard. Samples were solubilized in 8 M urea, 2%
CHAPS, 20 mM dithiothreitol (DTT), 0.5% ZOOM Carrier Ampholytes
3–10 (Invitrogen Japan K.K., Tokyo, Japan), and 0.002% bromophenol
blue. Protein lysates (50 μg) were separated on two-dimensional
PAGE gels. IPG strips, pH 3–10 NL or pH 4–7 (Invitrogen Japan K.K.),
were rehydrated overnight with the protein samples. Proteins were
separated based on their isoelectric point by IEF using the ZOOM IPG
Runner (Invitrogen Japan K.K.) with a maximal voltage of 2000 V and
50 μA per gel. Following IEF, IPG strips were incubated in equilibration
buffer I (6 M urea, 130 mM dithiothreitol, 30% glycerol, 45 mM Tris
base, 1.6% LDS, 0.002% bromophenol blue; Genomic Solutions) and
once in equilibration buffer II (6 M urea, 135 mM iodoacetamide, 30%glycerol, 45 mM Tris base, 1.6% LDS, 0.002% bromophenol blue;
Genomic Solutions) for 15 min each. Equilibrated IPG strips were
applied to 4–12% Bis–Tris gradient gels (Invitrogen Japan K.K.), and
the proteins were separated in the second dimension based on their
molecular size using NuPAGE MOPS buffer (Invitrogen Japan K.K.) at
200 V for 55 min. Following electrophoresis, gels were transferred
onto nitrocellulose and immunoblotted with the relevant antibodies.
The blots were probed with anti-argpyrimidine monoclonal antibody
(mAb6B), a kind gift from Prof. Koji Uchida (Nagoya University,
Japan), diluted 1:5000 in 0.1% (v⁄v) tween 20 blocking solution in TBS
for 2.5 h at room temperature. Immunoreactivity was detected using
an HRP-labeled secondary antibodywith an ECL PlusWestern blotting
detection reagents system. Each immunoblot was repeated three
times from independent experiments.
2.3. Immunoprecipitation
Cells were washed, collected, and resuspended in PBS. Cells were
pelleted by centrifugation and lysed in immunoprecipitation buffer
(Tris–HCl, pH 7.6, 150–400 mm NaCl, and 1% Nonidet P-40, 1 mm
EDTA, and protein inhibitors). The lysates were cleared by centrifu-
gation and were precleared by a 1-h incubation with 20 μl of a 50%
slurry of Protein A Sepharose Fast Flow (GE Healthcare UK Ltd.). The
cleared lysates were then incubated overnight with Hsp27 or Hsp25
polyclonal antibodies. Human Hsp27 polyclonal and mouse Hsp25
polyclonal antibodies detect endogenous levels of total human Hsp27
protein and mouse and rat Hsp25 protein, respectively. These
antibodies do not cross-react with other heat-shock proteins. The
antibody-captured complexes were recovered with fresh Protein A
Sepharose Fast Flow beads (20 μl of original bead slurry/sample) by
incubation with lysate/antibody mixture at 4 °C for 2 h. The beads
were then washed three times with the immunoprecipitation buffer.
SDS Laemmli buffer was added to the beads, and the beads were
boiled to elute the proteins. After centrifugation, the immunopreci-
pitated eluted proteins from the beads were subjected to SDS–PAGE
and Western blotting.
2.4. Tissue samples
MG modiﬁcation of Hsp27 was determined by immunoprecipita-
tion and Western blot analysis in ascending colon and rectum of 6
patients. This study was approved by the Ethics Committee of Kyoto
Prefectural University of Medicine (Kyoto, Japan) and informed
consent was obtained from all participants prior to enrollment. Six
specimens from patients (2 males and 4 females) with a mean age of
76±3 (range 73–80) years were clinically and pathologically
examined and diagnosed as adenoma and advanced cancer. The
tissue samples were immediately frozen in liquid nitrogen and stored
at −80 °C until use.
2.5. Proteomics of MG-modiﬁed Hsp27
Recombinant human Hsp27 (0.1 mg/ml) was incubated with
various concentrations of MG in 50 mM phosphate buffer (pH 7.4)
at 37 °C for 24 h. The monomers of native control Hsp27 and
MG-modiﬁed Hsp27 picked from the gels were rehydrated on ice
for 45 min in 50 mM ammonium bicarbonate containing 12.5 μg/μl
sequencing grade modiﬁed trypsin (Promega, Madison, WI). Diges-
tion was carried out at 37 °C for 15 h. The resulting peptides were
sequentially extracted for 20 min each in 50-μl aliquots of 20 mM
ammonium bicarbonate followed by 1% triﬂuoroacetic acid, 0.1%
triﬂuoroacetic acid in 50% acetonitrile and, ﬁnally, 5% acetic acid in
50% acetonitrile. Combined extracts were concentrated in a Speed Vac
to ~5 μl, re-dissolved in 45 μl of 0.1 M acetic acid, and centrifuged for
2 min at 14,000g. The supernatant fractions were carefully transferred
into a fresh tube and concentrated to ~5 μl. After evaporation, the
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tion mass spectrometry (MALDI-MS). MS analysis was performed
using an AXIMA Performance MALDI-TOF/TOF mass spectrometer
(Shimadzu Co., Kyoto, Japan), and alpha-cyano-4-hydroxycinnamic
acid (CHCA) solution was used as the MALDI matrix. MS/MS analysis
was performed using an AXIMA Resonance MALDI-QIT TOF mass
spectrometer (Shimadzu Co.), and 2,5-dihydroxybenzoic acid (DHB)
solution was used as the MALDI matrix. On the other hand, prior to
MS/MS analysis, the low molecular weight reactants were removed
from the crude reaction mixture containing MG and Hsp27 by
centrifugal ﬁltration (molecular weight cut-off of 10,000, Millipore).
Hsp27 and MG-modiﬁed Hsp27 (25 μg) were digested with trypsin in
0.2 ml of 100 mM Tris–HCl buffer (pH 8.0) at 37 °C for 24 h using an
enzyme:substrate ratio of 1:50 (w/w), followed by V8 protease in
Tris–HCl buffer (pH 7.8) at 37 °C for 18 h using an enzyme:substrate
ratio of 1:50 (w/w). The resulting peptides were analyzed by
LC-MALDI-TOF MS/MS using a Prominence nanoLC system and an
AXIMA-Performance MALDI-TOF/TOF mass spectrometer (Shimadzu
Co.). CHCA was used as the matrix.
2.6. Treatment of Hsp27 with BioPORTER
MG (0.5 mM)-modiﬁed, or native control Hsp27, was treated with
BioPORTER according to the manufacturer's instructions (Gene
Therapy Systems, Inc., San Diego, CA). Brieﬂy, the BioPORTER reagent
was suspended in methanol and 15 μl aliquots were air dried in 0.5 ml
Eppendorf tubes. One hundred microliters of PBS, containing 7.5 μg of
protein was added to each tube, thoroughly mixed by vortexing for
15 s, and then incubated at room temperature for 5 min. RIE cells in
DMEM/F12 containing 10% FCSwere cultured in six-well plates.When
cells reached 80% conﬂuence, the adherent cells were transferred into
new plates containing one of the following: BioPORTER alone,
BioPORTER with 7.5 μg of native control Hsp27, or BioPORTER with
7.5 μg of MG-modiﬁed Hsp27, in serum-free DMEM/F12. Cells were
incubated for 4 h at 37 °C in a humidiﬁed 5% CO2 atmosphere, and
then washed with PBS. Introduced native control Hsp27 and MG-
modiﬁed Hsp27 were quantitated by densitometric analysis of
Western blots using CS Analyzer—Image Analysis Software (ATTO
Corporation, Tokyo). Protein loading in all of the experiments was
normalized by stripping the blots and then reprobing with anti-
tubulin antibody. The ratio of introduced Hsp27 protein band density
to tubulin band density was calculated. Three independent experi-
ments were performed.
2.7. Assay of cell viability
After the introduction of native control Hsp27 and MG-modiﬁed
Hsp27 (MG-Hsp27) using BioPORTER, the cell viability was measured
using the 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H-tetrazolium, monosodium salt (WST-8) in Cell
Counting Kit-8 (Wako Pure Chemical Industries, Ltd.). In brief, treated
RIE cells were cultured in 96-well plates for 24 and 48 h, followed by
incubation with WST-8 for 4 h. Absorbance was measured at 450 nm,
and cell viability was determined by comparing the ratio of
absorbance for each experiment to that for the control experiments.
2.8. Apoptosis
To detect apoptotic cells, RIE cells were treated with hydrogen
peroxide and then labeled with annexin V-FITC and propidium iodide
(PI) for 15 min. Fluorescent cells were detected using FACSCalibur and
analyzed using the CellQuest analysis program (BD Biosciences,
Tokyo, Japan). For measurement of reactive oxygen species (ROS)
generation, RIE cells were incubated with aminophenyl ﬂuorescein
(APF), 2-[6-(4′-amino) phenoxy-3H-xanthen-3-on-9-yl] benzoic acid
(Invitrogen Japan K.K.), for 30 min, and then treated with hydrogenperoxide. The cells were scraped from the culture dishes, and
dispersed by pipetting as gently as possible to avoid mechanical
damage. Fluorescence intensity wasmeasured using a microtiter plate
reader (SpectraMax M2/M2e, Molecular Devices Corp. Tokyo, JAPAN),
with an excitationwavelength of 488 nm and an emissionwavelength
of 515 nm. Data were expressed as mean±SEM of three independent
measurements.
2.9. Activation of caspase-3 and caspase-9
Nuclei-free, mitochondria-free cytosolic extracts were prepared as
previously described [9]. Cell-free extracts (100 μg) derived from
Hsp27-introduced cells were incubated with 10 μM cytochrome c
from bovine heart (Sigma) and 1 mM dATP (Sigma) for 30 min. These
extracts were then incubated with 20 mM DEVD-AFC, or LEHD-AFC
(Calbiochem, San Diego, CA), at 37 °C for 90 min. Protein lysates
(200 μg) were incubated with 1.0 mM DEVD-AFC or LEHD-AFC at
37 °C for 90 min after apoptosis induction by treatment with
hydrogen peroxide. AFC released from the substrates was measured
using a microtiter plate reader with an excitation wavelength of
400 nm and an emission wavelength of 505 nm. Data were expressed
as mean±SEM of three independent measurements.
2.10. Measurement of L-lactate and D-lactate
The determination of D-lactate and L-lactate in RGM-1 and RGK-1
cells was performed by an enzymatic method based on the oxidation
of L-lactate and D-lactate to pyruvate by NAD in the presence of L-LDH
or D-LDH [11]. According to an instruction, in order to inactivate LDH,
cell lysates were heated at 80 °C for 15 min.
2.11. Statistical analysis
All values are expressed as means±SEM. The data were compared
using one-way analysis of variance (ANOVA) followed by Bonferroni's
Multiple Comparison Test. p-Valuesb0.05 were considered statisti-
cally signiﬁcant.
3. Results
3.1. MG-modiﬁed protein in gastrointestinal cancer cells
To search for protein modiﬁcations by MG, we used a proteomic
approach using two-dimensional (2D) gel electrophoresis and mass
spectrometry (MS) in rat gastric mucosal cell line RGM-1 and in rat
gastric mucosal carcinoma cell line RGK-1. RGK-1 cells are an
N-methyl-N′-nitro-N-nitrosoguanidine (MNNG)-induced mutant of
RGM-1 gastric epithelial cell line [10]. Themutant RGK-1 cell line form
tumors in all the mice injected after 3 weeks [10]. Whole protein
extracts from both RGM-1 and RGK-1 cells were separated by 2D
electrophoresis, followed by immunoblot analysis with an anti-MG-
modiﬁed protein monoclonal antibody. The monoclonal antibody
against MG-modiﬁed protein speciﬁcally recognizes argpyrimidine
[12]. A large variety of proteins were stained with an anti-
argpyrimidine antibody (Fig. 1A and D) because of endogenous MG
modiﬁcation derived from glycolysis. However, only in RGK-1 cells
but not in RGM-1 cells the immunoreactivity of a ~25 kDa protein was
identiﬁed by an antibody to argpyrimidine, as indicated by arrow
(Fig. 1D). It was expected that Hsp25 was modiﬁed by MG. Hsp25 in
the protein extracts obtained from RGM-1 and RGK-1 cells, was
conﬁrmed by immunoblotting using an anti-Hsp25 polyclonal
antibody (Fig. 1B and E). This anti-Hsp25 polyclonal antibody has
been shown to react with both the phosphorylated and the non-
phosphorylated forms of Hsp25 [13,14]. Hsp25 underwent various
post-translational modiﬁcations including phosphorylation, as shown
in Fig. 1B and E. The antibody against phosphorylated Hsp25/Hsp27
Fig. 1. Two-dimensional electrophoresis and Western blot analysis of proteins obtained from RGM-1 cells and RGK-1 cells. Whole cell extracts from RGM-1 cells (A–C) and RGK-1
cells (D–F) were separated by two-dimensional electrophoresis. MG-modiﬁed proteins were identiﬁed by immunoblot analysis using an anti-argpyrimidine antibody (A and D).
Hsp25 (indicated by arrows) was identiﬁed by immunoblotting using an anti-Hsp25 antibody (B and E). Total protein was stained with Deep Purple Total Protein Stain (C and F).
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Western blot analyses of RGM-1 cells and RGK-cells (data not shown).
This phosphorylated Hsp25/Hsp27 (Ser82) antibody detects endog-
enous Hsp25/Hsp27 only when phosphorylated at serine 82. The
antibody does not recognize other heat-shock proteins such as Hsp70
and Hsp90. Taken together, these results suggest that Hsp25 was
phosphorylated in both RGM-1 and RGK-1 cells, and was modiﬁed by
MG only in mutant RGK-1 cells but not in RGM-1 cells. In Fig. 2H,
Hsp25 expression levels were conﬁrmed byWestern blot analysis. The
same level of Hsp25 expression was observed in RGM-1 and RGK-1
cells. The modiﬁcation of Hsp25 with MG was veriﬁed by immuno-
precipitation study (Fig. 2Ha). Immunoprecipitated Hsp25 from
mutant RGK-1 cells was recognized by argpyrimidine antibody.
These ﬁndings were supported by immunoblot analysis in human
colon cancer cell line HT-29. Hsp27 (apparent molecular mass,
27 kDa) is the human homolog of rodent protein Hsp25 [15]. The
modiﬁcation of Hsp27 by MG was seen in HT-29 cells (Fig. 2A, B
and H). In addition, by using polyclonal antibody against phosphor-
ylated Hsp25/Hsp27 (Ser82) which is produced by immunizing
animals with a synthetic phospho-peptide corresponding to residues
surrounding Ser82 of human Hsp27, phosphorylation of Hsp27 was
also seen in HT-29 cells (Fig. 2C). Oligomerized Hsp27 (approximately
55 kDa)was also detected and this oligomerwas both phosphorylatedandMG-modiﬁed, as indicated by arrowhead (Fig. 2A, B and C). On the
other hand, Hsp25 in rat intestinal epithelial cell line RIE, which was
forcibly expressed by treatment with butyrate, was not modiﬁed by
MG (Fig. 2D and E). Moreover, young adult mouse colon epithelial cell
line YAMC showed no modiﬁcation of Hsp25 by MG (Fig. 2F and G).
RIE cells and YAMC cells do not express Hsp25 protein, but short-
chain fatty acids such as butyrate, propionate, and acetate in colonic
ﬂuid, are the major anions inducing a dose- and time-dependent
increase in Hsp25 expression [5]. These ﬁndings were conﬁrmed by
immunoprecipitation assay using anti-rat Hsp25 polyclonal antibody
which recognizes also mouse, bovine, dog, guinea pig and hamster
Hsp25. Immunoprecipitated Hsp25 from the RIE cells and the YAMC
cells were veriﬁed by using anti-Hsp25 monoclonal antibody and did
not show immunoreactivity to anti-argpyrimidine monoclonal anti-
body (Fig. 2Ha and b). Thus, immunoprecipitation studies revealed
that MGmodiﬁcations of both Hsp25 in RGK-1 cells and Hsp27 in HT-
29 cells are speciﬁc. Furthermore, in the ascending colon and rectum
of patients with cancer Hsp27 was modiﬁed by MG. Immunopreci-
pitated Hsp27 with polyclonal antibody from ascending colon and
rectum of patient with adenoma and advanced cancer showed cross-
reactivity with anti-argpyrimidine monoclonal antibody, whereas
that from normal subject showed no reactivity (Fig. 2Ha). The levels of
endogenous Hsp27 were conﬁrmed by using monoclonal antibody
Fig. 2. Detections of MG-modiﬁed proteins and Hsp25/Hsp27. Whole cell extracts from HT-29 cells (A–C), RIE cells (D and E), and YAMC cells (F and G) were separated by two-
dimensional electrophoresis. MG-modiﬁed proteins were identiﬁed by immunoblot analysis using anti-argpyrimidine (A, D, and F). Hsp27 (B) and phosphorylated Hsp27 (C) were
identiﬁed by immunoblot analysis using anti-Hsp27 and anti-pHsp27 (Ser-82), respectively. Forced expression of Hsp25 in RIE cells (D and E) and in YAMC cells (F and G) were
induced by treatment with butyrate. Hsp25 (indicated by arrows) was identiﬁed by immunoblot analysis using an anti-Hsp25 antibody (E and G). MGmodiﬁcations of Hsp25/Hsp27
were conﬁrmed by immunoprecipitation assays with Hsp25/Hsp27 and argpyrimidine speciﬁc antibodies (H). MG modiﬁcation in immunoprecipitated Hsp25/Hsp27 from whole
cell extracts and from tissue extracts were identiﬁed by immunoblot analysis using anti-argpyrimidine antibody (a). The immunoprecipitated Hsp25/27 were veriﬁed by
immunoblot analyses using anti-Hsp25 antibody (RGM-1, RGK-1, RIE, and YAMC cells) and anti-Hsp27 antibody (HT-29 cells and tissue of patients) (b).
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endogenous Hsp27 between cancer and normal. These results suggest
that MG modiﬁcation of Hsp25/Hsp27 contributes to the altered
metabolism of cancer. The expression level of Hsp25/Hsp27 was not
involved in the pathogenesis of cancer.3.2. MG modiﬁcation sites on Hsp27
To identify MGmodiﬁcation sites, human recombinant Hsp27 was
incubated with MG. Incubation of Hsp27 (0.1 mg/ml) and phosphor-
ylated Hsp27 (pHsp27, 0.1 mg/ml) with up to 5 mM MG in 50 mM
sodium phosphate buffer (pH 7.4) at 37 °C, resulted in a concentra-
tion-dependent polymerization, which was associated with the
covalent binding of MG to protein (Fig. 3). Moreover, immunoreac-
tivity with the anti-argpyrimidinemonoclonal antibody (mAb6B) was
observed in polymerized Hsp27. Native Hsp27 was more easily
polymerized by MG than phosphorylated Hsp27. To identify the MG
modiﬁcation sites on Hsp27, monomers of both the native and
MG-treated Hsp27 in the gels were digested with trypsin. The
resulting peptides were subjected to matrix-assisted laser desorp-
tion/ionization mass spectrometry (MALDI-MS). Sequence coverage
of both the native, andMG-modiﬁed Hsp27 (MG-Hsp27) was 67% and
63%, respectively. The MALDI-TOF MS spectra generated from native
Hsp27 and MG-Hsp27 are shown in Fig. 4A. To conﬁrm the MG
modiﬁcation sites, the MG-modiﬁed fragments were also analyzed
using a MALDI-QIT TOF mass spectrometer. The MS/MS spectrum of
the [M+H]+ ion at m/z 2882.5 from the MG-modiﬁed fragment with
the sequence LATQSNEITIPVTFESRAQLGGPEAAK, plus the mass
addition of 54 Da, is shown in Fig. 4B. In the MS/MS analysis, the
singly charged C-terminal product ions (y12–y13, y15, y17–y20, and
y23) and the lysine loss ions (y12-K and y17-K) were seen. The singlyFig. 3. Chemical modiﬁcation of Hsp27 by MG. MG-modiﬁed Hsp27 and MG-modiﬁed
phosphorylated Hsp27 were identiﬁed by immunoblot analysis using antibodies to
argpyrimidine (A) or Hsp27 (B).charged N-terminal product ions (b20, b22, and b24–b26) were also
observed, suggesting that the MGmodiﬁcation site in this sequence is
on Arg-188. This technique identiﬁed eleven peptides, which
containedMG adducts at Arg-136, Arg-188, and Lys-123. The peptides
identiﬁed by MALDI analysis of enzymatic digests of MG-Hsp27 are
listed in Table 1. These results suggest that 5-hydro-5-methylimda-
zolone, and carboxyethyllysine, are generated by MG modiﬁcation of
Hsp27.
To characterize the formation of argpyrimidine in MG-Hsp27,
MG-treated Hsp27 was digested with trypsin and V8 protease, and
then analyzed by LC-MALDI-TOF MS/MS. The sequence coverage of
MG-Hsp27 was 93%. The MS/MS spectrum of the [M+H]+ ion at m/z
1377.4 from the MG-modiﬁed fragment with the sequence
HGYISRCFTR, plus the mass addition of 80 Da, is shown in Fig. 4C.
The singly charged N-terminal product ions (b1–b9), and the singly
charged C-terminal product ions (y1–y10), were observed. Fig. 4D
shows the MS/MS spectrum of the [M+H]+ ion at m/z 1265.3 with
the sequence SRAQLGGPEAAK, plus the mass addition of 80 Da. In the
MS/MS analysis, single charged product ions (b1–b12 and y1–y12)
were observed. These data indicate that both Arg-136 and Arg-188
represent the MG modiﬁcation sites due to the 80 Da increase in the
mass value, and are due to argpyrimidine modiﬁcation. Peptides
identiﬁed by LC-MALDI analysis of the enzymatic digests of
MG-Hsp27 are listed in Table 1. This technique identiﬁed eleven
peptides, which contained MG adducts at Arg-5, Arg-37, Arg-56, Arg-
75, Arg-79, Arg-89, Arg-94, Arg-96, Arg-127, Arg-136, Arg-140, and
Arg-188. These results suggest that 5-hydro-5-methylimdazolone is
associatedwith Arg-5, Arg-37, Arg-56, Arg-75, Arg-79, Arg-89, Arg-94,
Arg-96, Arg-127, Arg-136, Arg-140, and Arg-188. Moreover, dihy-
droxyimidazolidine appears to associate with Arg-188.
The peptides identiﬁed by LC-MALDI analysis of enzymatic digests
of MG-modiﬁed phosphorylated Hsp27 (MG-pHsp27) are listed in
Table 2. Sequence coverage of MG-pHsp27 digested with both trypsin
and V8 protease was 72%. The MS/MS analyses showed that Hsp27
was phosphorylated, and 5-hydro-5-methylimdazolone, dihydroxyi-
midazolidine, and carboxyethyllysine were generated by MG modi-
ﬁcation of phosphorylated Hsp27. This technique identiﬁed 18
peptides, which contained MG adducts at Arg-75, Arg-89, Arg-94,
Arg-127, Arg-136, Arg-140, Arg-188, Lys-114 and Lys-123. 5-Hydro-5-
methylimdazolone was associated with Arg-75, Arg-89, Arg-94, Arg-
127, Arg-136, Arg-140, and Arg-188. Dihydroxyimidazolidine was
generated at Arg-75 and Arg-188. The association of argpyrimidine
with pHsp27 was not detected.
To verify that recombinant Hsp27 reﬂects the situation in vivo,
MG-Hsp27 and MG-pHsp27 were analyzed by 2D-PAGE followed by
Western blotting, and compared to Hsp27 both in HT-29 cells and in
inﬂamed mucosa of patient obtained from colonic biopsy (unpub-
lished data). It was difﬁcult to detect MG-Hsp27 in the ascending
colon and rectum of patients with cancer by 2D-PAGE followed by
Western blotting because of low protein concentrations. The results of
recombinant MG-Hsp27 and MG-pHsp27 were similar to those in
HT-29 cells. Recombinant MG-Hsp27 was detected as polymerized
andmigrated toward a more acidic pI form by 2D-PAGE. Recombinant
MG-pHsp27 was mainly detected around 25 kDa and 55 kDa. Both
recombinant MG-Hsp27 and MG-pHsp27 protein spots were also
detected as same positions as those from inﬂamed mucosa (unpub-
lished data).
3.3. Effect of MG modiﬁcation on apoptosis
It is known that Hsp27 prevents apoptosis [16]. To investigate the
effect of MG modiﬁcation on the anti-apoptotic properties of Hsp27,
we compared the protective effects of native unmodiﬁed Hsp27, and
MG-Hsp27, against hydrogen peroxide-induced apoptosis in RIE cells.
RIE cells do not express Hsp27 protein. Native Hsp27 and MG-Hsp27
were introduced into RIE cells using the BioPORTER reagent, which
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Fig. 4.MALDI-MS analyses of peptides from Hsp27 and MG-Hsp27. MS spectra of trypsin-digested native control Hsp27 and MG-modiﬁed Hsp27 (MG-Hsp27) peptides (A). MALDI-
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protease (D).
775T. Oya-Ito et al. / Biochimica et Biophysica Acta 1812 (2011) 769–781fuses directly with the plasma membrane and delivers the captured
protein into the cells by endocytosis; endosomes then release the
captured protein into the cytoplasm. The cells were incubated for up
to 48 h after introductions of native Hsp27 and MG-Hsp27, and cellTable 1
Peptides identiﬁed by MALDI-MS and LC-MALDI-TOF MS/MS analyses of enzymatic digests
Theoretical mass Start End Sequence
1041.25 5 12 R−VPFSLLR
1556.76 28 40 LFDQAFGLPR−LPE
2738.01 41 64 EWSQWLGGSSWPGYVR−PLPPAAIE
1570.75 65 79 SPAVAAPAYSR−ALSR
2412.61 65 87 SPAVAAPAYSR−ALSR−QLSSGVSE
1318.44 88 96 IR−HTADR−WR
2180.42 95 112 WR−VSLDVNHFAPDELTVK
1769.91 113 127 TKDGVVEITGK−HEER
2856.02 113 136 TKDGVVEITGK−HEERQDEHGYISR
1540.63 115 127 DGVVEITGK−HEER
2626.75 115 136 DGVVEITGK−HEERQDEHGYISR
2680.79 115 136 DGVVEITGK−HEER−QDEHGYISR
1709.73 124 136 HEER−QDEHGYISR
2274.39 124 140 HEERQDEHGYISR−CFTR
1722.84 128 140 QDEHGYISR−CFTR
1350.5 131 140 HGYISR−CFTR
1376.54 131 140 HGYISR−CFTR
1532.72 131 141 HGYISR−CFTR−K
2883.17 172 198 LATQSNEITIPVTFESR−AQLGGPEAAK
1238.35 187 198 SR−AQLGGPEAAK
1256.37 187 198 SR−AQLGGPEAAK
1264.39 187 198 SR−AQLGGPEAAKproliferation was measured by WST-8. The viability of RIE cells was
unaffected by the introduction of either native Hsp27 or MG-Hsp27
(Fig. 5A). To determine the effects of native Hsp27 and MG-Hsp27 on
apoptosis, the native unmodiﬁed Hsp27- and MG-Hsp27-introducedof MG-Hsp27. Modiﬁcation sites are underlined.
Modiﬁcations Enzyme
5-Hydro-5-methylimidazolone (R) Trypsin
5-Hydro-5-methylimidazolone (R) Trypsin+V8
5-Hydro-5-methylimidazolone (R) Trypsin+V8
5-Hydro-5-methylimidazolone (R) Trypsin+V8
2× 5-Hydro-5-methylimidazolone (R) Trypsin+V8
2× 5-Hydro-5-methylimidazolone (R) Trypsin+V8
5-Hydro-5-methylimidazolone (R) Trypsin
Carboxyethyllysine (K) Trypsin
Carboxyethyllysine (K) Trypsin
Carboxyethyllysine (K) Trypsin
Carboxyethyllysine (K) Trypsin
5-Hydro-5-methylimidazolone (R); carboxyethyllysine (K) Trypsin
5-Hydro-5-methylimidazolone (R) Trypsin
5-Hydro-5-methylimidazolone (R) Trypsin
5-Hydro-5-methylimidazolone (R) Trypsin
5-Hydro-5-methylimidazolone (R) Trypsin+V8
Argpyrimidine (R) Trypsin+V8
2× 5-Hydro-5-methylimidazolone (R) Trypsin+V8
5-Hydro-5-methylimidazolone (R) Trypsin
5-Hydro-5-methylimidazolone (R) Trypsin+V8
Dihydroxyimidazolidine (R) Trypsin+V8
Argpyrimidine (R) Trypsin+V8
Table 2
Peptides identiﬁed by MALDI-MS and LC-MALDI-TOF MS/MS analyses of enzymatic digests of MG-modiﬁed phosphorylated Hsp27. Modiﬁcation sites are underlined.
Theoretical mass Start End Sequence Modiﬁcations Enzyme
1041.01 13 20 GPS−WDPFR Phospho (S) Trypsin+V8
1041.01 13 20 GPS−WDPFR Phospho (S) Trypsin
1039.98 21 27 DWYPHS−R Phospho (S) Trypsin
1169.18 65 75 SPAVAAPAYS−R Phospho (S) Trypsin+V8
1650.73 65 79 SPAVAAPAYSR−ALSR Phospho (S); 5-hydro-5-methylimidazolone (R) Trypsin+V8
1668.74 65 79 SPAVAAPAYS−R−ALSR Phospho (S); dihydroxyimidazolidine (R) Trypsin+V8
1155.15 80 89 QLS−SGVSEIR Phospho (S) Trypsin
1789.8 80 94 QLS−SGVSEIR−HTADR Phospho (S); 5-hydro-5-methylimidazolone (R) Trypsin
922 88 94 IR−HTADR 5-Hydro-5-methylimidazolone (R) Trypsin+V8
1318.44 88 96 IR−HTADR−WR 2× 5-Hydro-5-methylimidazolone (R) Trypsin+V8
995.05 90 96 HTADR−WR 5-Hydro-5-methylimidazolone (R) Trypsin+V8
995.05 90 96 HTADR−WR 5-Hydro-5-methylimidazolone (R) Trypsin
1769.91 113 127 TKDGVVEITGK−HEER Carboxyethyllysine (K) Trypsin
1841.97 113 127 TK−DGVVEITGK−HEER 2× Carboxyethyllysine (K) Trypsin
1540.63 115 127 DGVVEITGK−HEER Carboxyethyllysine (K) Trypsin
1041.12 120 127 ITGK−HEER Carboxyethyllysine (K) Trypsin+V8
1709.73 124 136 HEER−QDEHGYISR 5-Hydro-5-methylimidazolone (R) Trypsin
1722.84 128 140 QDEHGYISR−CFTR 5-Hydro-5-methylimidazolone (R) Trypsin
1350.5 131 140 HGYISR−CFTR 5-Hydro-5-methylimidazolone (R) Trypsin+V8
1532.72 131 141 HGYISR−CFTR−K 2× 5-Hydro-5-methylimidazolone (R) Trypsin+V8
968.02 187 195 SR−AQLGGPE 5-Hydro-5-methylimidazolone (R) Trypsin+V8
1238.35 187 198 SR−AQLGGPEAAK 5-Hydro-5-methylimidazolone (R) Trypsin+V8
1256.37 187 198 SR−AQLGGPEAAK Dihydroxyimidazolidine (R) Trypsin+V8
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0.5 and 1.0 mM). Exposure to 1.0 mM hydrogen peroxide led to
necrosis. The intracellular delivery of native Hsp27 and MG-Hsp27 to
RIE cells was examined byWestern blot analysis (Fig. 5B). The density
of Hsp27 band was quantiﬁed by CS Analyzer—Image Analysis
Software. The ratio of band density of Hsp27 to band density of
tubulin was calculated. Native Hsp27 and MG-Hsp27 intracellular
delivery to RIE cells were 1.77 and 1.53, respectively. The treatment of
Hsp27- and MG-Hsp27-introduced cells with hydrogen peroxide did
not affect Hsp27 protein abundances. The same levels of Hsp27 and
MG-Hsp27 were observed after treatment with hydrogen peroxide.
The apoptotic RIE cells were assayed by ﬂow cytometry using FITC-
Annexin V binding and PI staining. Fig. 5C shows that 0.1 mM
hydrogen peroxide treatment results in an increase in FITC-Annexin
V-positive cells. The introduction of native Hsp27 decreased the
number of FITC-Annexin V positive cells induced by hydrogen
peroxide. The transfer of MG-Hsp27 into the cells dramatically
reduced the number of FITC-Annexin V positive cells. These results
suggest that the introduction of native Hsp27 delays the induction of
apoptosis, and the MG modiﬁcation of Hsp27 completely inhibits the
induction of apoptosis.
The efﬁcacy of MG modiﬁcation of Hsp27 on hydrogen peroxide-
induced intracellular ROS formation was evaluated. Native Hsp27,
pHsp27, MG-Hsp27 or MG-pHsp27 was introduced into RIE cells with
BioPORTER. To detect ROS, we used 2-[6-(4′-amino)phenoxy-3H-
xanthen-3-on-9-yl] benzoic acid (APF). APF can detect hydroxyl
radicals (·OH) and is completely resistant to autoxidation, both in
vitro and in vivo[17]. Hydrogen peroxide treatment caused an increase
in the amount of intracellular ·OH of BioPORTER-treated control RIE
cells in a concentration-dependentmanner (Fig. 6A). The introduction
of MG-Hsp27 prevented ·OH generation in the cells treated with
0.1 mM hydrogen peroxide compared with the introduction of native
Hsp27 or the BioPORTER-treated controls.
It is known that the formation of large oligomeric Hsp27 prevents
cytochrome c-mediated caspase activation [16], so we examined
whetherMGmodiﬁcation affected the regulation of caspase activation
by Hsp27 using a cell-free system. The addition of cytochrome c and
dATP to extracts from BioPORTER-treated control RIE cells resulted in
the activation of caspase-3 and caspase-9 (Fig. 6B). Extracts from
MG-pHsp27-introduced cells inhibited the activation of caspase-3,whereas no inhibition was observed by using extracts from native
Hsp27- or pHsp27-introduced cells. Caspase-9 activation was inhib-
ited by the introduction of all Hsp27 moieties (Hsp27, MG-Hsp27,
pHsp27, and MG-pHsp27; pb0.01 versus BioPORTER-treated control
cells). MG modiﬁcation did not affect the inhibition of caspase-9
activation by Hsp27. The introduction of pHsp27 was less effective in
inhibiting caspase-9 activation, but this inhibitory effect of pHsp27
was enhanced by MG modiﬁcation. These results suggested that MG
modiﬁcation of pHsp27 potentiate the suppression of cytochrome c-
mediated caspase activation.
We also determinedwhether Hsp27 introduction exerts a protective
effect against caspase activation during hydrogen peroxide-induced
apoptotic cell death. In BioPORTER-treated control RIE cells, both
caspase-3 and caspase-9 were activated by treatment with 0.1 mM
hydrogen peroxide. The introduction of Hsp27 into RIE cells prevented
both caspase-3 and caspase-9 activation, as shown in Fig. 6C. MG
modiﬁcation enhanced the inhibitory effect of Hsp27 on caspase-3
(pb0.01 versusHsp27-introduced cells) and caspase-9 (pb0.001 versus
Hsp27-introduced cells) activations. Phosphorylation of Hsp27 resulted
in the loss of this effect. MG modiﬁcation of pHsp27 increased the
inhibitory effects of both caspase-3 and caspase-9 activations, but the
overall effect was still less than that seen with Hsp27. These results
indicate that MG modiﬁcation is essential for conferring protection
against caspase-mediated apoptosis induced by hydrogen peroxide.
3.4. Intracellular levels of lactate, the principal end-product of MG
metabolism
It is difﬁcult to measure intracellular levels of MG directly because
of its high reactivity. MG reacts rapidly with guanidine group such as
arginine residue [12]. The glyoxalase system, comprising the
metalloenzymes glyoxalase I and glyoxalase II, is an almost universal
metabolic pathway involved in the detoxiﬁcation of the glycolytic
byproduct MG to D-lactate. Production of lactate in RGM-1 and RGK-1
cells was measured by using D-lactate and L-lactate dehydrogenase-
based assays (Fig. 8). The level of D-lactate in RGK-1 cells was found to
be signiﬁcantly higher compared with that in RGM-1 cells (2-fold,
pb0.05). The intracellular D-lactate contents of RGM-1 and RGK-1
cells were 0.06±0.01 and 0.13±0.01 mM/mg of cell lysate protein,
respectively. Moreover, the contents of L-lactate of RGM-1 and RGK-1
Fig. 5. Effect ofMGmodiﬁcationofHsp27onhydrogenperoxide-induced apoptosis. NativeHsp27, orMG-Hsp27,was introduced intoRIE cellswithBioPORTER. After incubation for 24 and
48 h at 37 °C, the effect of Hsp27 on cell viability was assessed by WST-8 (A). After a 4-h incubation, apoptosis was induced by treating the cells with hydrogen peroxide for 24 h. The
introductions of native Hsp27 andMG-Hsp27were assessed byWestern blot analysis (B). After treating cells with hydrogen peroxide for 24 h, cell extracts from Hsp27- andMG-Hsp27-
introduced cellswereexamined. Theextent of apoptosis inRIE cellswas assayed by FACS (FITC-AnnexinVbinding and PI staining) (a) BioPORTER-treated cells, (b)Hsp27-introduced cells,
(c) MG-Hsp27-introduced cells, (d) apoptosis analyzed by FITC-Annexin V binding (red: BioPORTER, green: BioPORTER+Hsp27, orange: BioPORTER+MG-Hsp27) (C).
777T. Oya-Ito et al. / Biochimica et Biophysica Acta 1812 (2011) 769–781cells were 0.32±0.01 and 0.77±0.01 mM/mg of cell lysate protein,
respectively. The level of L-lactate in RGK-1 cells was 2.4 times higher
than that in RGM-1 cells (pb0.00001). In RGK-1 and RGM-1 cells,
the concentration of D-lactate was one-sixth and one-ﬁfth ofconcentration of L-lactate, respectively. The total lactate content in
RGK-1 cells was 0.90±0.08 mM/mg of cell lysate protein, while that
in RGM-1 cells was 0.38±0.07 mM/mg of cell lysate protein. These
results support high levels of lactate in cancer cells.
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Fig. 6. Effects of MG modiﬁcation of Hsp27 on hydrogen peroxide-induced intracellular ROS formation and on caspase activation in RIE cells. Native Hsp27, phosphorylated Hsp27
(pHsp27), MG-Hsp27 or MG-pHsp27 was introduced into RIE cells with BioPORTER. ROS formation was induced by treating the cells with 0.1 mM hydrogen peroxide (A).
Intracellular ROS formation was detected with a ﬂuorescent probe, APF. The vertical bars represent SEM values of triplicate determinations. *pb0.05 versus BioPORTER-treated
control cells. Caspase activation was mediated by cytochrome c (B). Cell-free extracts from each RIE cells were treated with 10 μM cytochrome c and 1 mM dATP for 30 min. Caspase-
3 and caspase-9 activities were assessed by measuring the cleavage of the DEVD-AFC and LEHD-AFC substrates, respectively. **pb0.01 and ***pb0.001 versus BioPORTER-treated
control cells. Caspase activation was induced by treating the cells with 0.1 mM hydrogen peroxide (C). #pb0.01 and ##pb0.001 versus Hsp27-introduced cells.
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In this study, we identiﬁed a link between posttranslational
modiﬁcation and carcinogenesis. Rat Hsp25 and human Hsp27 were
identiﬁed as one of the major MG-modiﬁed proteins in gastrointes-
tinal cancer. Hsp27 is human homolog of rodent Hsp25 [15]. The
modiﬁcation of Hsp25 by MG was not seen in non-carcinogenetic
RGM-1 cells, RIE cells or YAMC cells. Immunoprecipitation studies
with anti-Hsp25/Hsp27 antibodies demonstrated that MG modiﬁca-
tion of Hsp25/Hsp27 is associated with cancer development.
In normal cells, Hsp27 participates in cytoskeletal, redox state and
protein folding homeostasis. It is also involved in the protection of
cells against stress. Hsp27 has beneﬁcial effects on protein confor-
mation and in inﬂammation-related diseases. High levels of consti-
tutive Hsp27 expression have been detected in several cancer cells,
particularly carcinomas [18,19]. Recently, the number of reportsdealing with Hsp27 in cancer pathology has grown exponentially.
Moreover, experiments in rodents have highlighted the tumorigenic
potential of Hsp27 expression [20]. Hsp27 is thought to increase the
ability of some cancer cells to resist and to evade the apoptotic
processes mediated by the immune system. In the current study, no
noticeable differences in expression level of Hsp25/Hsp27 between
noncancerous and cancerous cells were found. Additionally, MG
modiﬁcation was detected in only cancerous cells. It is expected that
MG modiﬁcation regulates the apoptotic processes. In future studies,
to explore the relationship between MG modiﬁcation and carcino-
genesis, LC-MALDI analysis of MG-modiﬁed Hsp27 in clinical sample
should be considered.
Recently, argpyrimidine formation in Hsp27 has been identiﬁed in
human non-small-cell lung carcinoma cells [3]. It has been uncertain
whether the concentration of MG is higher in gastrointestinal cancer
cells than in normal cells. It is difﬁcult to measure directly MG because
gastrointestinal 
cancer cells
MG-pHsp27 MG-Hsp27
MG
Hsp27
pHsp27
Cytochrome cCaspase-9Caspase-3
Fig. 7. A proposed mechanism for prevention of caspase activation by Hsp27. MG
modiﬁcation in gastrointestinal cancer cells promotes Hsp27 and pHsp27 properties.
779T. Oya-Ito et al. / Biochimica et Biophysica Acta 1812 (2011) 769–781of its high reactivity. Gluconeogenesis occurs without ATP consump-
tion through the MG pathway when used as a substrate of ketone
bodies via the pathway: butyric acid (butyrate) → beta-hydroxybu-
tyrate → acetoacetate → acetone → acetol → methylglyoxal →S-D-
lactol-glutathione → D -lactate → pyruvate → D-lactate [21]. It has
previously been reported that pyruvate concentration is signiﬁcantly
lower in colon tumors than in normal tissue, and slightly lower in
stomach tumors, whereas lactate concentration in tumor tissues is
higher in both tumor types than in normal tissue [2]. We measured
the levels of intracellular lactate which is the end molecule of the MG
pathway because MG is difﬁcult to measure directly. Indeed, the total
lactate content in MNNG-induced mutant of RGM-1 gastric epithelial
cell line, which is named RGK-1 cells, was dramatically higher than
that in RGM-1 cells (Fig. 8). This clearly indicates that cancer cells are
highly dependent on anaerobic breakdown of pyruvate. High lactate
dehydrogenase-5 activity, and the resulting increase in conversion of
pyruvate to lactate has been identiﬁed in colon cancer [22,23]. Active
glycolysis also increases the cytosolic NADH/NAD+ ratio, thereby
increasing the activity of lactate dehydrogenase [24]. Enhanced
pyruvate-to-lactate conversion may also be due to the activation of
the pyruvate dehydrogenase kinase, isozyme 1 (PDK1), in cancer cells,
which inactivates pyruvate dehydrogenase and leads to the inactiva-
tion of the TCA cycle [25]. Therefore, it is likely that cancer cells
preferentially use glucose because of intrinsic metabolic characteris-
tics, and micro-environmental factors such as hypoxia. Moreover, the
MG pathway represents an energetically unfavorable bypass to the
glycolytic reactions of the lower Embden–Meyerhof–Parnas pathway
using pyruvate [26,27]. Activation of the MG pathway has been
conﬁrmed when the intracellular uptake of glucose 6-phosphate or
other carbon substrates such as xylose, lactose, arabinose, glycerol or
gluconate are deregulated by mutation and/or by addition of cAMP0
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Fig. 8. Contents of D-lactate and L-lactate in RGK-1 cells and RGM-1 cells. Intracellular
lactate levels were estimated by D-lactate and L-lactate dehydrogenase-based assays.
*pb0.05 and **pb0.00001 versus RGM-1 cells.[28–30]. Moreover, the extremely low glucose content in tumor
tissues might result from both a poor blood supply and the high
glucose consumption by cancer cells. In addition, the glyoxalase
pathway catalyzes the formation of lactate fromMG in the presence of
glutathione. D-lactate is produced in the MG pathway as the end-
product of glyoxalase II enzymatic reaction. The intracellular D-lactate
concentration in RGK-1 cells was twice as high as that in RGM-1 cells
(pb0.05). There is an increase in the ﬂux of MGmetabolized to lactate
via the glyoxalase pathway with high glucose concentrations [31].
RGK-1 cells are the ﬁrst MNNG-induced neoplastic mutant cells
derived from a noncancerous, nonembryonic gastric epithelial cell
line. Ultrastructural results show homogenous, dense secretory
granules and deformed mitochondria in RGK-1 cells [10]. RGM-1
cells have no secretory granules, normal-shaped mitochondria, and
abundant polyribosomes. Moreover, mutant RGK-1 cells have shown
tumorigenic potential in all mice into which they have been injected
[10]. We consider that the intracellular accumulation of MG is
implicated in the pathogenesis of cancer in RGK-1 cells. It is important
to determine whether high MG modiﬁcation promotes the develop-
ment of cancer. Because the intracellular MG concentration is
regulated by glyoxalase, the experiments of overexpression or
knockdown of glyoxalase should be done in the future.
The large oligomers of Hsp27, which bear chaperone-like activity,
are also responsible for the tumorigenic activity of Hsp27 [32].
Therefore, it cannot be excluded that large Hsp27 oligomers may act
in a manner similar to Hsp90, and bind speciﬁc client proteins that
participate in the tumorigenic and metastatic processes. In this study,
numerous post-translational modiﬁcations of Hsp25/Hsp27 in a large
number of cancer cells were found. Recombinant Hsp27 and
phosphorylated Hsp27 were polymerized during incubation with
MG in vitro. Moreover, large MG-modiﬁed Hsp27 and MG-modiﬁed
pHsp27 oligomers were detected in tumorigenic HT-29 cells. It is
suggested that the polymerizations of Hsp27 and pHsp27 are
promoted by modiﬁcation of MG. In Fig. 3, cross-linked Hsp27 and
pHsp27 increased with increasing concentration of MG. Previous
research has demonstrated that chaperone-like activity of Hsp27,
even pHsp27, is greatly facilitated by MG modiﬁcation [9]. Addition-
ally, Hsp modiﬁcation by MG enhances the hydrophobicity [33]. The
chaperone function of alpha-crystallin is attributed to hydrophobic
regions of the protein, and modiﬁcation by low concentration of MG
increases its hydrophobicity [33]. Hsp27 also has hydrophobic N-
terminal region that contributes to its oligomerization [34]. An
increased molecular chaperone function in cancer cells is likely
related to oligomerization of Hsp27 by MG modiﬁcation and an
increased hydrophobicity. Future studies will investigate the effect of
MG modiﬁcation on chaperone function in cancer cells.
The formation of argpyrimidine on Hsp27 has also been identiﬁed
in endothelial cells [35], lens epithelial cells [9] and rat kidney
mesangial cells [36], indicating that Hsp27 is a protein highly
susceptible to MGmodiﬁcation. MALDI-MS/MS analysis of the peptide
fragments derived from recombinant human Hsp27 showed MG
modiﬁcation sites at Arg-5, Arg-96, Arg-127, Arg-136, Arg-188, and
Lys-123. For the ﬁrst time, we conﬁrmed the formation of argpyr-
imidine on trypsin- and V8 protease-digested fragments of MG-
modiﬁed Hsp27 by LC-MALDI-TOF MS/MS analysis. However, we
failed to detect argpyrimidine adducts in the peptide fragments
derived from MG-modiﬁed phosphorylated Hsp27. It is unclear
whether MG is insensitive to pHsp27 or whether the peptide
fragments derived fromMG-pHsp27 are beyond the limit of detection.
The upper limit of detectable mass range is approximately 35,000 Da.
At least immunoreactivity against argpyrimidine was observed with
polymerized MG-pHsp27 in our experiments. Meanwhile, it has been
shown that MG forms a number of adducts with lysine residues in
polymerized proteins. Nagaraj et al. [33] have described an imidazo-
lium cross-link structure, imidazolysine. In this study, because the
antibody does not recognize imidazolysine [12], this structure was not
780 T. Oya-Ito et al. / Biochimica et Biophysica Acta 1812 (2011) 769–781searched in the data base of LC-MALDI-TOF MS/MS analyses. It is
predicted that imidazolium cross-link structures are generated inMG-
modiﬁed Hsp27.
As described previously, Hsp27 is expressed throughout the body
and plays an important role in cellular functions such as apoptosis [9]
and actin polymerization [37–39]. In stressed cells, increased levels of
Hsp27 facilitate the repair, or destruction, of damaged proteins, thus
promoting cell recovery. In our previous study, we found that Hsp27
shows increased anti-apoptotic effects in lens epithelial cells after
modiﬁcation by MG, which is due to multiple mechanisms including
the enhancement of chaperone function, and inhibition of caspase
activity [9,33,40]. The transfer of MG-modiﬁed Hsp27 signiﬁcantly
inhibits staurosporine-induced apoptotic cell death and ROS produc-
tion in a human lens epithelial cell line (HLE B-3) [9]. In this study, RIE
cells also exhibited enhanced anti-apoptotic property by MG
modiﬁcation of Hsp27. In particular, MG modiﬁcation of Arg-188 in
Hsp27 is essential for inhibiting cytochrome c-mediated caspase
activation in 293T cells transfected with mutant of Hsp27 (Arg-188 to
glycine) [41]. MALDI-MS/MS analysis of the peptide fragments
derived fromMG-modiﬁed Hsp27 showed that Arg-188 is susceptible
to modiﬁcation. YAMC cells expressed Hsp25 by treatment with
butyrate were not resistant to hydrogen peroxide-induced apoptosis
(data not shown). Additionally, we found that the expression levels of
Hsp25 showed no difference between RGM-1 cells and mutant RGK-1
cells. Our experiments, especially immunoprecipitation assays,
showed that the expressed Hsp25 in RIE cells and YAMC cells by
treatment with butyrate was not modiﬁed by MG, whereas Hsp25 in
mutant RGK-1 cells and Hsp27 in HT-29 cells and in ascending colon
and rectum of patient with adenoma and advanced cancer were.
These results suggest that MG modiﬁcation of Arg-188 in Hsp25/
Hsp27 plays a key role in the development of cancer. It was impossible
to detect MG modiﬁcation of Arg-188 in protein extracts from
cultured cells and clinical samples by MALDI-MS analysis due to low
expression level. Future studies are needed to conﬁrm the effect of
Arg-188 in Hsp25/Hsp27 in cancer cells.
It has been speculated that MG may protect cells against hypergly-
cemia-induced damage in diabetes because MG modiﬁcation of Hsp27
enhances its chaperone function, as has been shown for alpha-crystallin
[9,33]. However, protein-modifying sugars and ascorbic acid have no
such effect and actually reduce chaperone function [33]. Thus, it is
believed that MG modiﬁcation of Hsp27 is different from other
glycation. Additionally, a study in human lens epithelial cells indicated
that MG modiﬁcation enhances the binding of Hsp27 to cytochrome c
and, subsequently, the protection from caspase-3 dependent cell death
[9]. Our experiments showed that the transfer of Hsp27 using a cationic
lipid inhibits the hydrogen-peroxide-induced apoptosis in the RIE cell
line and that MG modiﬁcation of Hsp27 enhances this inhibition. The
introduction of MG-Hsp27 reduced intracellular ROS generation also.
MG-modiﬁed Hsp27 showed no difference in proliferation of rat
intestinal epithelial cell line compared to other controls (Hsp27, vehicle,
and BP-treatment). When apoptosis was mediated by the addition of
both cytochrome c and ATP to the cell-free cytosol, the inhibition of
caspase-3 activation by phosphorylated Hsp27, and of caspase-9
activation by both native and phosphorylated Hsp27, was enhanced
by MG modiﬁcation. This shows that MG modiﬁcation of pHsp27
prevents the activations of both caspase-3 and caspase-9 induced by the
release of cytosolic cytochrome c from mitochondria. Moreover, MG
modiﬁcation of native Hsp27 and phosphorylated Hsp27 inhibited the
activations of both caspase-3 and caspase-9 during oxidant-induced cell
death. These results suggest that Hsp27 reacts immediately with MG
and serves protective functions against caspase activation in gastroin-
testinal cancer cells (Fig. 7). The enhanced inhibitory effects of MG
modiﬁcation on caspase activation are similar to those seen for
chaperone activity [9]. We propose that MG modiﬁcation of Hsp27
can protect against caspase-3 and caspase-9 activations without
affecting the rate of cytochrome c release and promote cell survival.Almost all phosphorylated Hsp27 were modiﬁed by MG in lens
epithelial cells [9] and in HT-29 cells. Thus, while MG modiﬁcation of
Hsp27 can maintain transparency and protect against apoptosis in lens
cells which has a slow turnover rate, this modiﬁcation may be involved
in the pathogenesis of cancer in the gastrointestinal epithelium which
has a rapid turnover rate.
In conclusion, the speciﬁc immunoreactivity against the MG-
modiﬁed protein was observed in gastrointestinal carcinoma cell lines
and in ascending colon and rectum of patients with cancer, but not in
normal subjects. We identiﬁed this modiﬁed protein as Hsp25/Hsp27
and showed for the ﬁrst time that argpyrimidine adducts are
generated at Arg-136 and Arg-188 of MG-modiﬁed Hsp27, which is
thought to be necessary for its enhanced anti-apoptotic effects.
Furthermore, we found that MG-modiﬁed Hsp27 effectively inhibits
caspase activation, ROS production, and the induction of apoptosis in
hydrogen peroxide-treated cells. Therefore, our results suggest that
posttranslational modiﬁcation of Hsp27 by MG may contribute to the
development of gastrointestinal cancer.
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